Lamivudine/zidovudine + efavirenz - Strides Pharma Science
Alternative Names: Zidovudine/lamivudine + efavirenzLatest Information Update: 03 Dec 2018
Price :
$50 *
At a glance
- Originator Strides Arcolab
- Developer Strides Pharma Science
- Class Alkynes; Antiretrovirals; Azides; Benzoxazines; Cyclopropanes; Deoxyribonucleosides; Dideoxynucleosides; Nucleosides; Pyrimidine nucleosides; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered HIV-1 infections
Most Recent Events
- 03 Dec 2018 Chemical structure information added
- 21 Nov 2018 Lamivudine/zidovudine co-packaged with efavirenz is not yet avaliable in USA for HIV-1 infections (Stride Pharma website, November 2018)